Retrospective primary-care data from England presented at EASD 2026 found that adults with type 2 diabetes starting tirzepatide reached an HbA1c below 6.5% at roughly twice the rate of those on injectable or oral semaglutide (46.3% versus 20.6% and 23.8%) over 12 months. Weight loss of at least 15% occurred in 24.1% of tirzepatide patients compared with 9.1% and 8.4% on semaglutide. Because glycemic burden and excess adiposity both compress healthspan, a therapy that moves both endpoints simultaneously carries implications well beyond diabetes management.
Key Points
- Tirzepatide reached HbA1c under 6.5% in 46.3% of patients
- 15% weight loss achieved by 24.1% versus 9.1% on semaglutide
- Retrospective propensity-matched records; no adherence, cost or safety data reported
Longevity Analysis
Dual GIP/GLP-1 agonism appears to act on two interlinked failure points at once: the glucose handling that drives glycation and vascular injury, and the fat mass that sustains low-grade inflammatory signaling. Judging metabolic therapy on a single blood marker understates what is actually at stake over decades, and a wider scorecard changes how clinicians interpret treatment success. The data describe one year of outcomes in people who remained on therapy, which leaves open the questions that determine long-term benefit — persistence, lean mass preservation, and what happens to the metabolic set point when the drug stops.
Original published by Longevity.Technology, by Kyle Umipig.